Curebase is a San Francisco-based eClinical software company building an AI-powered platform that runs clinical trials around patients' lives instead of inside hospital walls. Its single system spans study startup to database lock - combining electronic data capture (EDC), eConsent, ePRO/eCOA, patient recruitment, and a virtual research site model - so sponsors can launch decentralized and hybrid trials faster, capture cleaner data, and reach more diverse participant populations.
Medidata Solutions is a New York-based, cloud software company that runs the digital plumbing of modern clinical research. Its flagship Rave EDC pioneered electronic data capture in clinical trials, and today its unified platform spans data capture, patient engagement, AI analytics, imaging, and trial operations. A Dassault Systèmes company since 2019, Medidata powers trials for most of the world's largest pharmaceutical companies and has supported the development of a large share of newly approved drugs and medical devices.
Medable is a Palo Alto-based digital health company building a cloud SaaS platform for decentralized and hybrid clinical trials. Its tools - eCOA+, Total Consent, Sensors, and Televisit - let pharma sponsors and CROs run studies remotely, enrolling patients in over 60 countries and 120+ languages.
Medrio is a San Francisco-based eClinical software company that helps pharma, biotech, medtech and diagnostics teams run clinical trials with a no-code, cloud-based EDC, eCOA/ePRO, eConsent and RTSM suite. Founded in 2005 and bootstrapped for more than a decade before taking outside capital, Medrio now powers thousands of studies across four continents.
Tom Lemberg is the Founder & CEO of Curebase, a San Francisco-based decentralized clinical trial platform that has enrolled over 60,000 patients across 60+ studies. A Harvard-trained computer scientist and molecular biologist, Lemberg built Curebase from his couch in 2017, joined Y Combinator in 2018, and raised $59M to transform how clinical trials work - letting patients participate from home and bringing their own doctors into the research process. Named to Forbes 30 Under 30 in 2022, he's on a mission to make clinical trials accessible to any patient, anywhere.